NASDAQ:CBIO Catalyst Biosciences (CBIO) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.34▼$7.6752-Week Range N/AVolume32,246 shsAverage Volume763,526 shsMarket Capitalization$291.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Catalyst Biosciences alerts: Email Address Ad Stansberry ResearchGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."Click here now to watch this exclusive interview About Catalyst Biosciences Stock (NASDAQ:CBIO)Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.Read More Ad Stansberry ResearchGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."Click here now to watch this exclusive interview CBIO Stock News HeadlinesFebruary 10, 2024 | seekingalpha.comNeurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional UpsideJanuary 5, 2024 | markets.businessinsider.comBuy Rating Backed by Pivotal Trial Catalyst and Novel Drug Delivery Platform for Cellectar BiosciencesJuly 27, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.November 1, 2023 | businesswire.comBiocom California Names the Eighth Annual Life Science Catalyst Award WinnersOctober 30, 2023 | finance.yahoo.comCatalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock SplitOctober 23, 2023 | ft.comGeneral Catalyst in German VC tie-up as part of European tech pushOctober 18, 2023 | foxnews.com'Blind Side' author Michael Lewis suggests catalyst behind Michael Oher lawsuit: 'Violence and aggression'August 23, 2023 | finance.yahoo.comIs Catalyst Biosciences (CBIO) Significantly Overvalued?July 27, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 22, 2023 | investing.comCatalyst Biosciences (CBIO) Earnings Dates & ReportsJune 9, 2023 | finance.yahoo.comCBIO - Catalyst Biosciences, Inc.April 28, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHBI, CBIO, TA, ASRTApril 3, 2023 | finance.yahoo.comCatalyst Biosciences, Inc. (NASDAQ:CBIO) insiders placed bullish bets worth US$941k in the last 12 monthsMarch 31, 2023 | insidermonkey.com5 Cheap Healthcare Stocks to Buy in 2023March 31, 2023 | markets.businessinsider.comRaymond James Sticks to Its Hold Rating for Catalyst Biosciences (CBIO)March 29, 2023 | finance.yahoo.com12 Cheap Healthcare Stocks to Buy in 2023March 9, 2023 | prnewswire.comCATALYST BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Catalyst Biosciences, Inc. - CBIOFebruary 28, 2023 | msn.comCatalyst Biosciences Shares Are Rallying: What's Driving The Action?See More Headlines Receive CBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/17/2023Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:CBIO CUSIP87611R30 CIK1124105 Webwww.catalystbiosciences.com Phone(650) 871-0761Fax336-480-2107Employees7Year Founded2003Profitability EPS (Most Recent Fiscal Year)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-364.68% Return on Assets-281.68% Debt Debt-to-Equity RatioN/A Current Ratio2.88 Quick Ratio2.88 Sales & Book Value Annual Sales$790,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.78) per share Price / BookN/AMiscellaneous Outstanding Shares37,980,000Free Float36,869,000Market Cap$291.29 million OptionableOptionable Beta1.05 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Nassim Usman Ph.D. (Age 63)President, CEO & Director Comp: $1.75MMs. Seline E. Miller CPA (Age 54)Senior VP of Finance, Interim Chief Financial & Principal Accounting Officer Comp: $707.55kMs. Ana KaporSenior Director of Investor Relations & Corporate CommunicationsKey CompetitorsAdamas PharmaceuticalsNASDAQ:ADMSAclaris TherapeuticsNASDAQ:ACRSZynerba PharmaceuticalsNASDAQ:ZYNETyme TechnologiesNASDAQ:TYMEEquilliumNASDAQ:EQView All Competitors CBIO Stock Analysis - Frequently Asked Questions How were Catalyst Biosciences' earnings last quarter? Catalyst Biosciences, Inc. (NASDAQ:CBIO) released its earnings results on Thursday, August, 17th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). When did Catalyst Biosciences' stock split? Shares of Catalyst Biosciences reverse split on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 10th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Catalyst Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Catalyst Biosciences investors own include Baozun (BZUN), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO), Amarin (AMRN), ImmunoGen (IMGN) and Sarepta Therapeutics (SRPT). This page (NASDAQ:CBIO) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.